In a recent phase III clinical trial, an oral PI3K inhibitor, alpelisib, in combination with fulvestrant prolonged the progression-free survival of patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer28, suggesting PIK3CA as a candidate target for cervical cancer treatment. This evidence concerns the gene PIK3CA and cervical carcinoma.